+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Digital Biomarkers Market: Focus on Key Trends, Growth Potential, Competitive Landscape, Components, End Users, Application (Sleep and Movement, Neuro, Respiratory and Cardiological Disorders) and Region - Analysis and Forecast, 2019-2025

  • ID: 4871610
  • Report
  • March 2020
  • Region: Global
  • 433 Pages
  • BIS Research

FEATURED COMPANIES

  • ActiGraph, LLC
  • Amgen Inc
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Koninklijke Philips N.V.
  • Mindstrong Health

Key Questions Answered in the Report:


  • What are the total addressable market (TAM) and the potential market opportunity for the global digital biomarkers market?
  • What are the major market drivers and challenges of, and the opportunities in, the global digital biomarkers market?
  • What is the market share of the leading segments and sub-segments of the global digital biomarkers market in 2019 and 2025?
  • How did the global digital biomarkers market evolve?
  • How is each segment of the global digital biomarkers market expected to grow during the forecast period and what is the expected revenue to be generated by each of the segments by the end of 2025?
  • What are the consumer preferences in terms of the adoption of wearable technology for the assessment of medical conditions?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What is the preferred business model used for building digital biomarkers?
  • Which area of application is expected to be the highest revenue generator in the global digital biomarkers market during the forecast period?
  • Which end-user segment is expected to be the highest revenue generator in this industry during the forecast period?
  • What is the potential of the global digital biomarkers market in emerging countries during the forecast period?

Global Digital Biomarkers Market Forecast, 2019-2025

The Global Digital Biomarkers Market Report projects the market to grow at a significant CAGR of 40.39% during the forecast period from 2019 to 2025. There are multiple factors that drive the market, such as the surge in the demand for mobile health apps and consumer wearable technology specifically for tracking health. For instance, as of 2019, about 35% of the U.S. adult population (18 to 29 years) track their health with the help of mobile apps while 27% of the adults own and use a wearable device for monitoring heart rate, blood pressure, physical activity, or other vitals.

Furthermore, the data generated from wearable devices are increasingly being validated through studies based on clinical trials. For instance, the number of clinical trials conducted using wearable devices was consistent during the period of 2008 to 2018, i.e. 5-12 trials annually. However, the number surged significantly in 2016 and 2017, with 27 and 32 trials (using mobile devices) commencing each year respectively. The primary reason for this rise in such trials in 2016 and 2017 can be attributed to the considerable surge in the sponsorship for these studies.

Expert Quote on the Global Digital Biomarkers Market

According to Swarup Chakrabarty, an analyst, “Cardiovascular disease segment is currently the largest therapeutic segment for the global digital biomarkers market and holds a share of 31.75% of the market, followed by neurodegenerative diseases with a share of 20.63%. During the forecast period, pain management, and mood and behavior segments, are expected to witness the highest CAGR of 59.07% and 45.34%, respectively. The growth in the pain management segment is primarily due to increasing development and adoption of AR/VR solutions for the detection and treatment of chronic pain.”

Scope of the Market Intelligence on Global Digital Biomarkers Market

The purpose of this study is to gain a holistic view of the global digital biomarkers market in terms of various influencing factors such as regional adoption trends, technological advancements, and pricing patterns.

The scope of this report constitutes an in-depth study of the global digital biomarkers market, including a thorough analysis of the products in the market as well as their adoption spanning different regions. The market has been chiefly segmented into components, applications, end-user, and regions. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

Market Segmentation

The Global Digital Biomarkers Market can be segmented on the basis of component type, application, end-user, and region. As of 2018, biopharma companies held an estimated 57% of the global digital biomarkers market. Numerous collaborations and partnerships were witnessed in 2017 and 2018,  aimed at developing digital solutions for the clinical assessment of various disorders such as cardiovascular, neurodegenerative, and respiratory. Some of the notable biopharma companies engaging in partnership activities include Takeda, Biogen, and Sanofi among others. A significant contribution was also witnessed by healthcare providers, who held an estimated 42% of the global digital biomarkers market in 2018.

During the forecast period (2019-2025), the health insurance payers are expected to evolve as the largest end-user segmented in the global digital biomarkers market. The growth rate for this segment is expected to be 44.04% during the forecast period. This high growth rate is primarily due to the increasing use of digital biomarkers by payer groups to effectively devise individualized care plans.

In terms of region, Asia-Pacific is the largest market in the digital biomarkers space and is expected to remain the same during the forecast period. North America is also contributing to the growth of this space. The elevated level of smartphone and wearable technology in these regions, as well as the high incidence of lifestyle-related diseases, are pushing consumers in the region to monitor their medical conditions.

However, during the forecast period, Europe is expected to attain the highest CAGR of 41.99%. The growth is primarily due to increasing standardization and collaboration among key stakeholders in the industry.

Key Companies in the Global Digital Biomarkers Market

Some of the major key players in the global digital biomarkers market include ActiGraph, LLC., Akili Interactive Labs, AliveCor, Inc., Fitbit, Inc., HumanAPI, Novartis, Pfizer Inc. F. Hoffmann-La Roche Ltd, Sanofi, Takeda Pharmaceuticals, and Verily Life Science LLC.


Enterprise License customers will receive an Excel spreadsheet containing additional data.


Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ActiGraph, LLC
  • Amgen Inc
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Koninklijke Philips N.V.
  • Mindstrong Health


Executive Summary
1 Product Definition
1.1 Products Considered
2 Scope of the Report
3 Research Methodology
3.1 Global Digital Biomarkers Market: Research Methodology
3.1.1 Primary Data Sources
3.1.2 Secondary Data Sources
4 Digital Biomarkers: Global Perspective
4.1 Definition
4.2 Current State of Digital Biomarkers
4.3 Digital Biomarkers Ecosystem
4.3.1 Digital Platforms
4.3.1.1 Wearables Devices
4.3.1.2 Implantable Components/Sensors
4.3.1.3 Ingestible Sensors
4.3.1.4 Ocular Devices
4.3.1.5 Accelerometers
4.3.1.6 Smart Home Systems/IOTs
4.3.1.7 AR/VR Platforms
4.3.1.8 Desktop/Web Apps
4.4 Data Measurements
4.4.1 Physiological Parameters
4.4.2 Behavioral Parameters
4.5 Types of Biomarkers
4.5.1 Wellness
4.5.2 Disease
4.5.3 Drugs
4.6 Industry
4.6.1 Pharmaceutical
4.6.2 Biotechnology/Life Sciences
4.6.3 Medical Devices
4.6.4 App Vendors
4.6.5 Clinical Trials (Clinical Research Organizations)
4.6.6 Technology Vendors
4.7 Digital Biomarkers: Technology Landscape
4.7.1 Artificial Intelligence and Machine Learning
4.7.2 Augmented Reality and Virtual Reality
4.7.3 Blockchain
4.7.4 Edge Computing
4.7.5 Cloud Computing
4.8 Successful Case Studies: Key Therapeutic Areas
4.8.1 Cardiovascular Disease
4.8.2 Parkinson’s Disease
4.8.3 Alzheimer’s Disease
4.8.4 Huntington's disease
5 Market Dynamics
5.1 Growth-Promoting Factors
5.1.1 Explosion of Wearable Devices and Increasing Smartphone Penetration
5.1.2 Increasing Cost of Drug Development
5.1.3 Failure of Drugs for Neurodegenerative Disorder
5.1.4 Regulatory Flexibility Toward Digital Health Solutions
5.2 Market Challenges
5.2.1 Need for Standardized and Interoperable Solutions
5.2.2 Difference or Inaccuracy in Data Measurements
5.2.3 Lack of Integration and Interoperability Between Medical Records and User Generated Data
5.2.4 Lack of Use Cases Pertaining to the Return on Investment (ROI) Analysis
5.3 Market Opportunities
5.3.1 Digital Biomarkers: The Future of Precision Medicine
5.3.2 Investment in Voice-Based Digital Biomarkers
5.3.3 Investment in Wearable Technology
5.3.3.1 Early Detection of Neurological Disorders
5.3.3.2 For General Health Management
5.3.3.3 Metabolic, Cardiovascular, and Gastrointestinal Health
5.3.3.4 Maternal, Pre- and Neo-Natal Care
5.3.3.5 Pulmonary Health and Environmental Exposures
6 Competitive Landscape
6.1 Key Strategies and Developments
6.1.1 Synergistic Interactions
6.1.2 Product Launches and Enhancements
6.1.3 Business Expansion and Funding Activities
6.1.4 Acquisitions, Approvals, and Others
7 Digital Biomarker Market Opportunities and Growth, 2018-2025 ($Million)
7.1 Data Collection (Sensors and Tools that Collect Data)
7.1.1 Wearables Devices
7.1.1.1 Evolution of Wearable Devices in Clinical Trials
7.1.1.2 Wearable Devices in Clinical Trials
7.1.1.3 Actigraphy Devices
7.1.1.3.1 Generational Change from Polysomnography to Actigraphy
7.1.1.3.2 ActiGraph
7.1.1.4 Market Estimation and Forecast, 2018-2025
7.1.1.5 Opportunity in Digital Biomarker
7.1.1.6 New Developments
7.2 Implantable/Ingestible Biosensors
7.2.1 Market Estimation and Forecast, 2018-2025
7.2.2 Opportunity in Digital Biomarker
7.3 Mobile/Tablet Apps
7.3.1 Market Estimation and Forecast, 2018-2025
7.3.2 Opportunity in Digital Biomarker
7.3.3 New Developments
7.3.4 Competitive Landscape
7.4 Data Integration
7.4.1 Market Estimation and Forecast, 2018-2025
7.4.2 Competitive Landscape
7.5 Global Digital biomarkers Market (by Application)
7.5.1 Gastrointestinal Diseases
7.5.1.1 Inflammatory Bowel’s Disease
7.5.2 Sleep and Movement
7.5.3 Cardiovascular
7.5.4 Mood and Behavior (Psychiatric Disorders)
7.5.5 Chronic Pain
7.5.6 Neurodegenerative Disorders
7.5.6.1 Parkinson’s Disease
7.5.6.2 Multiple Sclerosis
7.5.6.3 Alzheimer’s Disease
7.5.7 Diabetes
7.5.8 Respiratory Conditions
7.5.9 Others
8 Global Digital Biomarkers Market, by End Users
8.1 Biopharmaceutical Companies
8.1.1 Role of Biopharma Companies in the Development of Digital Biomarkers
8.1.2 Major Therapeutic Areas for Biomarkers
8.1.2.1 Respiratory Diseases
8.1.2.2 Neurodegenerative Diseases
8.1.2.3 Cardiovascular Diseases
8.1.2.4 Diabetes
8.2 Payers
8.3 Providers
9 Global Digital Biomarkers Market (by Region)
9.1 North America
9.1.1 U.S
9.1.1.1 Digital Health Scenario
9.1.1.2 Degree of Adoption of Wearables
9.1.1.3 Degree of Adoption of Mobile Health Applications
9.1.1.4 Local Players in the Digital Biomarker Market
9.1.1.5 Regulatory Scenario
9.1.2 Canada
9.1.2.1 Digital Health Scenario
9.1.2.2 Degree of Adoption of Wearables
9.1.2.3 Degree of Adoption of Mobile Health Applications Adoption
9.1.2.4 Local Digital Biomarker Market
9.1.2.5 Regulatory Scenario
9.1.2.6 Future of Digital Health in Canada
9.2 Europe
9.2.1 Netherlands
9.2.1.1 Digital Health Scenario
9.2.1.2 Level of Wearables Adoption
9.2.1.3 Degree of Adoption of Mobile Health Applications
9.2.1.4 Local Players in the Digital Biomarker Market
9.2.2 Germany
9.2.2.1 Digital Health Scenario
9.2.2.2 Degree of Adoption of Wearables
9.2.2.3 Reluctance to Fitness Trackers
9.2.2.4 Future of Digital Health in Germany
9.2.3 U.K.
9.2.3.1 Digital Health Scenario
9.2.3.2 Degree of Adoption of Wearables
9.2.3.3 Increasing Sales of Smartwatches
9.2.3.4 Abandonment of Wearables
9.2.3.5 Local Players in Wearables
9.2.4 France
9.2.4.1 Digital Health Scenario
9.2.4.2 Degree of Wearables Adoption
9.2.4.3 Local Players in Digital Biomarkers Market
9.2.5 Spain
9.2.5.1 Digital Health Scenario
9.2.5.2 Degree of Adoption of Wearables
9.2.6 Italy
9.2.6.1 Digital Health Scenario
9.2.6.2 Degree of Adoption of Wearables
9.2.6.3 Degree of Adoption of Mobile Health Applications
9.2.7 Russia
9.2.7.1 Digital Health Scenario
9.2.7.2 Degree of Adoption of Wearables
9.2.7.3 Degree of Adoption of Mobile Health Applications
9.2.8 Rest-of-Europe
9.2.8.1 Digital Health Scenario
9.2.8.2 Degree of Adoption of Wearables
9.2.8.3 Degree of Adoption of Mobile Health Applications
9.2.8.4 Local Player in Digital Biomarker Market
9.3 Asia-Pacific
9.3.1 China
9.3.1.1 Digital Health Scenario
9.3.1.2 Degree of Adoption of Wearables
9.3.1.3 Degree of Adoption of Mobile Health Applications
9.3.1.4 Local Players in Digital Biomarker Market
9.3.2 Japan
9.3.2.1 Digital Health Scenario
9.3.2.2 Degree of Wearables Adoption
9.3.2.3 Degree of Mobile Health Applications Adoption
9.3.2.4 Local Players in Digital Biomarker Market
9.3.3 South Korea
9.3.3.1 Digital Health Scenario
9.3.3.2 Degree of Adoption of Wearables
9.3.3.3 Degree of Adoption of Mobile Health Applications
9.3.4 India
9.3.4.1 Digital Health Scenario
9.3.4.2 Degree of Adoption of Wearables
9.3.4.3 Degree of adoption of Mobile Health Applications
9.3.4.4 Local Players in Digital Biomarker Market
9.3.5 Australia
9.3.5.1 Digital Health Scenario
9.3.5.2 Level of Wearables Adoption
9.3.5.3 Level of Mobile Health Applications Adoption
9.3.6 Singapore
9.3.6.1 Digital Health Scenario
9.3.6.2 Degree of Adoption of Wearables
9.3.6.3 Degree of Adoption of Mobile Health Applications
9.3.7 Rest-of-Asia-Pacific
9.3.7.1 Digital Health Scenario
9.3.7.2 Degree of adoption of Wearables and Mobile Health Application
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Digital Health Scenario
9.4.1.2 Degree of Adoption of Wearables
9.4.1.3 Degree of Adoption of Mobile Health Applications
9.4.2 Mexico
9.4.2.1 Digital Health Scenario
9.4.2.2 Degree of Adoption of Wearables
9.4.2.3 Degree of Adoption of Mobile Health Applications
9.5 Rest-of-the-World
9.5.1 Saudi Arabia
9.5.1.1 Digital Health Scenario
9.5.1.2 Degree of Adoption of Wearables
9.5.1.3 Degree of Adoption of Mobile Health Applications
9.5.2 U.A.E.
9.5.2.1 Digital Health Scenario
9.5.2.2 Degree of Adoption of Wearables and Mobile Health Applications
9.5.3 Israel
9.5.3.1 Digital Health Scenario
9.5.3.2 Degree of Adoption of Wearables
9.5.4 South Africa
9.5.4.1 Digital Health Scenario
9.5.4.2 Degree of Adoption of Wearables
9.5.4.3 Degree of Adoption of Mobile Health Applications
10 Company Profiles
10.1 Overview
10.2 ActiGraph, LLC
10.2.1 Company Overview
10.2.2 Role of ActiGraph, LLC in the Global Digital Biomarkers Market
10.2.3 Recent Developments
10.2.4 SWOT Analysis: ActiGraph, LLC
10.3 Akili Interactive Labs
10.3.1 Company Overview
10.3.2 Role of Akili Interactive Labs in the Global Digital Biomarkers Market
10.3.3 Recent Developments
10.3.4 SWOT Analysis
10.4 AliveCor Inc.
10.4.1 Company Overview
10.4.2 Role of AliveCor, Inc. in the Global Digital Biomarkers Market
10.4.3 Recent Development
10.4.4 SWOT Analysis
10.5 Altoida AG
10.5.1 Company Overview
10.5.2 Role of Altoida AG in the Global Digital Biomarkers Market
10.5.3 Recent Developments
10.5.4 SWOT Analysis
10.6 Amgen Inc
10.6.1 Company Overview
10.6.2 Role of Amgen Inc. in the Global Digital Biomarkers Market.
10.6.3 Financials
10.6.4 Key Insights About Financial Health of the Company
10.6.5 Recent Developments
10.6.6 SWOT Analysis
10.7 Bayer AG
10.7.1 Company Overview
10.7.2 Role of Bayer AG in the Global Digital Biomarkers Market
10.7.3 Financials
10.7.4 Key Insights About Financial Health of the Company
10.7.5 Recent Developments
10.7.6 SWOT Analysis
10.8 Biogen Inc.
10.8.1 Company Overview
10.8.2 Role of Biogen Inc. in the Global Digital Biomarkers Market
10.8.3 Financials
10.8.4 Key Insights About Financial Health of the Company
10.8.5 Recent Developments
10.8.6 SWOT Analysis
10.9 Eli Lilly and Company
10.9.1 Company Overview
10.9.2 Role of Eli Lilly and Company in the Global Digital Biomarkers Market
10.9.3 Financials
10.9.4 Key Insights About Financial Health of the Company
10.9.5 Recent Developments
10.9.6 SWOT Analysis
10.10   Evidation Health, Inc.
10.10.1 Company Overview
10.10.2 Role of Evidation Health, Inc. in the Global Digital Biomarker Market
10.10.3 Recent Developments
10.10.4 SWOT Analysis
10.11   F. Hoffmann-La Roche Ltd
10.11.1 Company Overview
10.11.2 Role of F. Hoffmann-La Roche Ltd in the Global Digital Biomarkers Market
10.11.3 Financials
10.11.4 Key Insights About Financial Health of the Company
10.11.5 Recent Developments
10.11.6 SWOT Analysis
10.12   Fitbit, Inc.
10.12.1 Company Overview
10.12.2 Role of Fitbit Inc. in the Global Digital Biomarker Market
10.12.3 Financials
10.12.4 Key Insights About Financial Health of the Company
10.12.5 Recent Developments
10.12.6 SWOT Analysis
10.13   GlaxoSmithKline Plc
10.13.1 Company Overview
10.13.2 Role of GlaxoSmithKline Plc in the Global Digital Biomarkers Market
10.13.3 Financials
10.13.4 Key Insights About Financial Health of the Company
10.13.5 Recent Developments
10.13.6 SWOT Analysis
10.14   Human API
10.14.1 Company Overview
10.14.2 Role of Human API in the Global Digital Biomarkers Market
10.14.3 Recent Developments
10.14.4 SWOT Analysis
10.15   Happify Health
10.15.1 Company Overview
10.15.2 Role of Happify Health in the Global Digital Biomarker Market
10.15.3 Recent Developments
10.15.4 SWOT Analysis
10.16   IXICO Plc
10.16.1 Company Overview
10.16.2 Role of IXICO Plc in the Global Digital Biomarkers Market
10.16.3 Financials
10.16.4 Key Insights About Financial Health of the Company
10.16.5 Recent Developments
10.16.6 SWOT Analysis
10.17   Koninklijke Philips N.V.
10.17.1 Company Overview
10.17.2 Role of Koninklijke Philips N.V. in the Global Digital Biomarkers Market
10.17.3 Financials
10.17.4 Key Insights About Financial Health of the Company
10.17.5 Recent Developments
10.17.6 SWOT Analysis
10.18   Medopad Ltd
10.18.1 Company Overview
10.18.2 Role of Medopad Ltd in the Global Digital Biomarker Market
10.18.3 Recent Developments
10.18.4 SWOT Analysis
10.19   Mindstrong Health
10.19.1 Company Overview
10.19.2 Role of Mindstrong Health in the Global Digital Biomarker Market
10.19.3 Recent Developments
10.19.4 SWOT Analysis
10.20   Neurotrack Technologies, Inc.
10.20.1 Company Overview
10.20.2 Role of Neurotrack Technologies, Inc in the Global Digital Biomarker Market
10.20.3 Recent Developments
10.20.4 SWOT Analysis
10.21   Novartis International AG
10.21.1 Company Overview
10.21.2 Role of Novartis International AG in the Global Digital Biomarkers Market
10.21.3 Financials
10.21.4 Key Insights About Financial Health of the Company
10.21.5 Recent Developments
10.21.6 SWOT Analysis
10.22   Orikami
10.22.1 Company Overview
10.22.2 Role of Orikami in the Global Digital Biomarker Market
10.22.3 Recent Developments
10.22.4 SWOT Analysis
10.23   Pfizer Inc.
10.23.1 Company Overview
10.23.2 Role of Pfizer Inc in the Global Digital Biomarkers Market
10.23.3 Financials
10.23.4 Key Insights About Financial Health of the Company
10.23.5 Recent Developments
10.23.6 SWOT Analysis
10.24   Quanterix Corporation
10.24.1 Company Overview
10.24.2 Role of Quanterix Corporation in the Global Digital Biomarker Market
10.24.3 Financials
10.24.4 Key Insights About Financial Health of the Company
10.24.5 Recent Developments
10.24.6 SWOT Analysis
10.25   Sanofi S.A.
10.25.1 Company Overview
10.25.2 Role of Sanofi S.A. in the Global Digital Biomarker Market
10.25.3 Financials
10.25.4 Key Insights About Financial Health of the Company
10.25.5 Recent Developments
10.25.6 SWOT Analysis
10.26   The Takeda Pharmaceuticals Company Limited
10.26.1 Company Overview
10.26.2 Role of The Takeda Pharmaceuticals Company Limited in the Global Digital Biomarkers Market
10.26.3 Financials
10.26.4 Key Insights About Financial Health of the Company
10.26.5 Recent Developments
10.26.6 SWOT Analysis
10.27   Verily Life Sciences
10.27.1 Company Overview
10.27.2 Role of Verily Life Sciences in the Global Digital Biomarkers Market
10.27.3 Recent Developments
10.27.4 SWOT Analysis: Verily Life Sciences
Company Snapshots
10.28   Cambridge Cognition Plc
10.28.1 Company Overview
10.28.2 Role of Cambridge Cognition Plc. in the Global Digital Biomarkers Market
10.28.3 Recent Developments
10.29   MC10 Inc.
10.29.1 Company Overview
10.29.2 Role of MC10 Inc. in the Global Digital Biomarkers Market
10.29.3 Recent Developments
10.30   Medical Care Corporation
10.30.1 Company Overview
10.30.2 Role of Medical Care Corporation in the Global Digital Biomarkers Market
10.31   Shimmer
10.31.1 Company Overview
10.31.2 Role of Shimmer in the Global Digital Biomarkers Market
10.31.3 Recent Developments
10.32   Winterlight Labs Inc.
10.32.1 Company Overview
10.32.2 Role of Winterlight Labs, Inc. in the Global Digital Biomarkers Market
10.32.3 Recent Developments
List of Tables
Table 1: A Comparison Between Examples of Clinical Biomarkers and Digital Biomarkers
Table 2: Percentage of Different Wearable Technology Brands Being Used in Clinical Trials (As of December 2019, N=1600)
Table 3: Regional Perspective: From Consumer (Non-Clinical) Generated Data, $Million, 2018-2025
Table 4: Regional Perspective: Patient-Centric Data During Clinical Trials, $Million, 2018-2025
Table 4.1: Different Categories of Mobile Health Applications
Table 5.1: Leading Wearable Devices and Their Features
Table 5.2: Major FDA Clearances in 2019
Table 6.1: Synergistic Activities Share (by Company), January 2016– September 2019
Table 6.2: Product Launches and Enhancements Share (by Company), January 2016 – September 2019
Table 6.3: Business Expansion and Funding Activities Share (by Company), January 2016 – September 2019
Table 6.4: Key Acquisitions in the global digital biomarkers Space (2019)
Table 7.4: Distribution of Clinical Trials Performed Using Wearable Connected Devices (Up to Dec 2019)
Table 7.5: ActiGraph Objective Measures
Table 7.6: Recent Key Developments in the Digital Biomarker Space in Terms of Wearable Devices
Table 7.7: Some of the recent developments in this segment
Table 7.9: Potential Digital Tools for the Measurement of Outcomes for Inflammatory Bowel’s Disease
Table 7.10: Overview of Clinical Trials Performed Using Mobile Application for the Monitoring/Management of IBD
Table 7.11: Commercially Available Mobile Apps Used for the Monitoring and Management of Inflammatory Bowel’s Disease
Table 7.14: Clinical Trials Using Mobile Application for the Assessment of Sleep-Related Disorders:
Table 7.15: Clinical Trials Using Wearable Devices for the Assessment of Sleep-Related Disorders
Table 7.16: Some of the key developments in the Field of Sleep Disorders Using Digital Health
Table 7.17: Overview of Clinical Trials Performed Using Mobile Application for the Monitoring/Management of Cardiovascular Diseases
Table 7.18: Overview of Clinical Trials Performed Using Wearable Devices for the Monitoring/Management of Cardiovascular Diseases
Table 7.19: Recent Developments Using Wearable Developments for the Assessment of Cardiovascular Diseases
Table 7.20: Clinical Trials Using Actigraphy devices for the Assessment of Mood Disorders
Table 7.22: Recent Developments in the Mood Related Disorders Space
Table 7.23: Number of Clinical Trials Using a Mobile Application, 2019
Table 7.24: Increased Use of Wearable Devices in Clinical Trials for Chronic Pain
Table 7.25: Recent Key Developments in the Field of Digital Tech Assisted Chronic Pain Management
Table 7.26: Top 5 Clinical Trials on Parkinson’s Disease Conducted Using Smartphone Apps
Table 7.27: Some of the Clinical Trials on Parkinson’s Disease Conducted Using Wearable Devices
Table 7.28: Top 5 Clinical Trials on Multiple Sclerosis Conducted Using Smartphone Apps
Table 7.29: Some of The Clinical Trials on Multiple Sclerosis Conducted Using Wearable Devices
Table 7.30: Top 5 Clinical Trials on Alzheimer’s Disease Conducted Using Smartphone Apps
Table 7.31: Some of the Clinical Trials on Alzheimer’s Disease Conducted Using Wearable Devices
Table 7.32: Recent Developments in the Neurodegenerative Disease Space Pertaining to Digital Biomarkers
Table 7.33: Clinical Trials Using Mobile Application for the Management of Diabetes:
Table 7.34: Clinical Trials Using Wearable Devices to Manage Diabetes
Table 7.35: Key Developments Involving Wearables/Mobile Application in the Management of Diabetes
Table 7.36: Leading Respiratory Conditions and Related Deaths
Table 7.37: Top 5 Clinical Trials on Respiratory Disease Conducted Using Mobile Apps
Table 7.38: Some of the Clinical Trials on Respiratory Disease Conducted Using Wearable Devices
Table 7.39: Recent Developments in the Respiratory Segment
Table 9.1: Different Types of Health Tracking People and Their Characteristics
Table 9.4: Rate of Usage of Wearables in Italy
Table 9.5: Different Classes of Mobile Application in Healthcare and their Rate of Usage (%)
Table 9.6: Different European Countries and the Level of Adoption of Consumer Wearables (in Percentage, 2019)
Table 9.7: Different Wearables and Their Adoption Rates in Australia
Table 9.8: Different Wearables and Their Expected Adoption Rates in Australia
Table 9.9: Different Wearables and Their Adoption Rates in Singapore
Table 9.10: Different Wearables and Their Expected Adoption Rates in Singapore
Table 9.11: Different Wearables and Their Adoption Rates in Mexico
Table 9.12: Different Wearables and Their Expected Adoption Rates in Singapore
Table 10.1: Clinical Trials Involving Devices from ActiGraph, LLC
Table 10.2: Akili Interactive Labs: Clinical Trials
Table 10.3: AliveCor, Inc.: Clinical Trials
Table 10.4: Altoida AG: Clinical Trials
Table 10.5: Bayer AG: Clinical Trial
Table 10.6: Biogen Inc.: Clinical Trial
Table 10.7: Eli Lilly and Company: Clinical Trials
Table 10.8: Evidation Health, Inc.: Clinical Trials
Table 10.9: F. Hoffmann-La Roche Ltd: Clinical Trials
Table 10.10: Fitbit, Inc.: Clinical Trials
Table 10.11: GlaxoSmithKline Plc: Clinical Trials
Table 10.12: Happify Health: Clinical Trials
Table 10.13: Koninklijke Philips N.V.
Table 10.14: Medopad Ltd: Clinical Trials
Table 10.15: Mindstrong Health: Clinical Trials
Table 10.16: Neurotrack Technologies, Inc.: Clinical Trials
Table 10.17: Novartis International AG: Clinical Trials
Table 10.18: Pfizer Inc:  Clinical Trials
Table 10.19: Quanterix Corporation: Clinical Trials
Table 10.20: Verily Life Sciences: Projects
Table 10.21: Verily Life Sciences: Clinical Trials
Table 10.22: MC10 Inc: Clinical Trials
Table 10.23: Shimmer: Clinical Trials
Table 10.24: Winterlight Labs, Inc: Clinical Trials
List of Figures
Figure 1: Global Subscriber Base and Smartphone Penetration
Figure 2: Number of Clinical Trials Using Connected Wearable Devices by Year (Cumulative)
Figure 3: Percentage of Completed and Active Clinical Trials Using Wearables (As of December 2019, N=1600)
Figure 5: Global Digital Biomarkers Market (by Type), $Million, 2018-2025
Figure 6: Global Digital Biomarkers Market, Provider Type (Data Collection), $Million, 2018-2025
Figure 7: Global Digital Biomarkers Market, Data Collection System Type, $Million, 2018-2025
Figure 8: Global Digital Biomarkers Market, Data Integration System Providers, $Million, 2018-2025
Figure 9: Global Digital Biomarkers Market (Application/Therapeutic Area), $Million, 2018-2025
Figure 10: Share of Leading Therapeutic Areas in the Digital Biomarkers Market, 2018 and 2025 (Market Size: 2018 = $524.6 million, 2025 = $5.63 billion)
Figure 11: Global Digital Biomarkers Market (End Users), $Million, 2018-2025
Figure 12: Current Penetration of Different End User Groups in the Digital Biomarkers  Market (2018)
Figure 2.1: Global Digital Biomarkers Market: Breakup of the Market
Figure 3.1: Global Digital Biomarkers Market Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Data Triangulation
Figure 3.5: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.6: Top-Down Approach (Segment-Wise Analysis)
Figure 3.7: Assumptions and Limitations
Figure 3.8: Considered Factors for Data Prediction and Modeling
Figure 3.9: Scope Definition for the Global Digital Biomarkers Market
Figure 4.1: Major Components of Digital Biomarkers Market
Figure 4.2: A Flowchart Depicting the Conversion of Healthcare Data to a Digital Biomarker
Figure 4.3: Different Populations of Data Producers of Digital Biomarkers
Figure 5.1: Number of Alzheimer's Disease Drug Under Development
Figure 6.1: Share of Key Developments and Strategies, January 2016–September 2019 (Total Developments = 106)
Figure 7.1: Global Digital Biomarker Data Collection Market ($million), 2018-2025
Figure 7.2: Wearable Devices and its Market Share (in Units) in Global Healthcare Sector
Figure 7.3: Clinical Trials Using Connected Wearable Devices by Year (Cumulative)
Table 7.1: Number of Clinical Trials Performed Using Different Brands of Wearables Catering to Diverse Therapeutic Areas (Cumulative, As of 2019)
Table 7.2: Distribution of Number of Clinical Trials Using Wearable Devices, by Country (Up to Dec 2019)
Table 7.3: A Comparative Analysis on the Commercially Available Actigraphy Devices
Figure 7.4: Distribution of Number of Clinical Trials Using Actigraphy Devices, by Region (Cumulative as of 2019)
Figure 7.5: Distribution of Number of Clinical Trials Using ActiGraph Devices, by Therapeutic Areas (Cumulative as of 2019)
Figure 7.6: Evolution of Four Generations of ActiGraph Activity Monitors
Figure 7.7: Global Wearable Devices Digital Biomarkers Market ($million), 2018-2025
Figure 7.8: Global Implantable Components/Biosensors Market, $Million, 2018-2025
Figure 7.9: Global Mobile/Tablet Apps Market, $Million, 2018-2025
Figure 7.10: Global Data Integration Systems Market, $Million, 2018-2025
Figure 7.11: Global Digital Biomarkers Market, Application Type: Gastrointestinal Diseases, $Million, 2018-2025
Figure 7.12: Global Digital Biomarkers Market, Application Type: Sleep Disorders, $Million, 2018-2025
Figure 7.13: Global Digital Biomarkers Market, Application Type: Cardiovascular, $Million, 2018-2025
Figure 7.14: Global Digital Biomarkers Market, Application Type: Mood and Behavior, $Million, 2018-2025
Figure 7.15: Global Digital Biomarkers Market, Application Type: Chronic Pain, $Million, 2018-2025
Figure 7.16: Global Digital Biomarkers Market, Application Type: Neurodegenerative Disorders, $Million, 2018-2025
Figure 7.17: Global Digital Biomarkers Market, Application Type: Respiratory Conditions, $Million, 2018-2025
Figure 7.18: Global Digital Biomarkers Market, Application Type: Respiratory Conditions, $Million, 2018-2025
Figure 7.19: Global Digital Biomarkers Market, Application Type: Other Therapeutic Areas, $Million, 2018-2025
Figure 8.1: Potential Use Cases of Digital Biomarkers (From an End User Perspective)
Figure 8.2: Global Digital Biomarkers Market, End User Type: Biopharma companies, $Million, 2018-2025
Figure 8.3: Global Digital Biomarkers Market, End User Type: Health Insurance Payers, $Million, 2018-2025
Figure 8.4: Global Digital Biomarkers Market, End User Type: Healthcare Providers, $Million, 2018-2025
Figure 9.1: North America Digital Biomarkers Market, Clinical Trials, $Million, 2018-2025
Figure 9.2: North America Digital Biomarkers Market, Non-Clinical, $Million, 2018-2025
Figure 9.3: Factors Influencing Digital Biomarkers Market in North America
Figure 9.4: U.S. Digital Biomarkers Market, $Million, 2018-2025
Figure 9.5: U.S. Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.6: Canada Digital Biomarkers Market, $Million, 2018-2025
Figure 9.7: Canada Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.8: Mobile Health Applications: Usage Areas (As of 2019)
Figure 9.9: Europe Digital Biomarkers Market, $Million, 2018-2025
Figure 9.10: Factors Influencing Digital Biomarkers Market in Europe
Figure 9.11: Netherlands Digital Biomarkers Market, $Million, 2018-2025
Figure 9.12: Netherlands Digital Biomarkers Market, by Settings, $Million, 2018-2025
Figure 9.13: Germany Digital Biomarkers Market, $Million, 2018-2025
Figure 9.14: Germany Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.15: U.K. Digital Biomarkers Market, $Million, 2018-2025
Figure 9.16: U.K. Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.17: France Digital Biomarkers Market, $Million, 2018-2025
Figure 9.18: France Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.19: Spain Digital Biomarkers Market, $Million, 2018-2025
Figure 9.20: Spain Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.21: Italy Digital Biomarkers Market, $Million, 2018-2025
Figure 9.22: Italy Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.23: Russia Digital Biomarkers Market, $Million, 2018-2025
Figure 9.24: Russia Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.25: Belgium Digital Biomarkers Market, $Million, 2018-2025
Figure 9.26: Sweden Digital Biomarkers Market, $Million, 2018-2025
Figure 9.27: Denmark Digital Biomarkers Market, $Million, 2018-2025
Figure 9.28: Norway Digital Biomarkers Market, $Million, 2018-2025
Figure 9.29: Asia-Pacific Digital Biomarkers Market, $Million, 2018-2025
Figure 9.30: Factors Influencing Digital Biomarkers Market in Asia-Pacific
Figure 9.31: China Digital Biomarkers Market, $Million, 2018-2025
Figure 9.32: China Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.33: Japan Digital Biomarkers Market, $Million, 2018-2025
Figure 9.34: Japan Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.35: South Korea Digital Biomarkers Market, $Million, 2018-2025
Figure 9.36: South Korea Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.37: India Digital Biomarkers Market, $Million, 2018-2025
Figure 9.38: India Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.39: Australia Digital Biomarkers Market, $Million, 2018-2025
Figure 9.40: Australia Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.41: Singapore Digital Biomarkers Market, $Million, 2018-2025
Figure 9.42: Latin America Digital Biomarkers Market, $Million, 2018-2025
Figure 9.43: Factors Influencing Digital Biomarkers Market in Latin America
Figure 9.44: Brazil Digital Biomarkers Market, $Million, 2018-2025
Figure 9.45: Brazil Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.46: Mexico Digital Biomarkers Market, $Million, 2018-2025
Figure 9.47: Mexico Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.48: Rest-of-the-World Digital Biomarkers Market, $Million, 2018-2025
Figure 9.49: Factors Influencing Digital Biomarkers Market in Rest-of-the-World
Figure 9.50: Saudi Arabia Digital Biomarkers Market, $Million, 2018-2025
Figure 9.51: Saudi Arabia Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.52: U.A.E. Digital Biomarkers Market, $Million, 2018-2025
Figure 9.53: U.A.E. Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.54: Israel Digital Biomarkers Market, $Million, 2018-2025
Figure 9.55: Israel Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.56: South Africa Digital Biomarkers Market, $Million, 2018-2025
Figure 9.57: South Africa Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 10.1: Total Number of Companies Profiled
Figure 10.2: ActiGraph, LLC: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.3: ActiGraph, LLC.: SWOT Analysis
Figure 10.4: Akili Interactive Labs: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.5: Akili Interactive Labs: SWOT Analysis
Figure 10.6: AliveCor, Inc: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.7: AliveCor Inc.: SWOT Analysis
Figure 10.8: Altoida, AG: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.9: Altoida AG.: SWOT Analysis
Figure 10.10: Amgen Inc: Overall Financials, 2016-2018
Figure 10.11: Amgen Inc. Revenue (by Region), 2016-2018
Figure 10.12: Amgen Inc.  R&D Expenditure, 2016-2018
Figure 10.13: Amgen Inc: SWOT Analysis
Figure 10.14: Bayer AG.: Overall Financials, 2016-2018
Figure 10.15: Bayer AG: Revenue (by Segment), 2016-2018
Figure 10.16: Bayer Inc: Revenue (by Region), 2016-2018
Figure 10.17: Bayer AG: R&D Expenditure, 2016-2018
Figure 10.18: Bayer AG: SWOT Analysis
Figure 10.19: Biogen Inc: Overall Financials, 2016-2018
Figure 10.20: Biogen Inc.: Revenue (by Region), 2016-2018
Figure 10.21: Biogen Inc.: R&D Expenditure, 2016-2018
Figure 10.22: Biogen Inc: SWOT Analysis
Figure 10.23: Eli Lilly and Company: Overall Financials, 2016-2018
Figure 10.24: Eli Lilly and Company: Revenue (by Segment), 2016-2018
Figure 10.25: Eli Lilly and Company: Revenue (by Region), 2016-2018
Figure 10.26: Eli Lilly and Company: R&D Expenditure, 2016-2018
Figure 10.27: Eli Lilly and Company: SWOT Analysis
Figure 10.28: Evidation Health, Inc.: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.29: Evidation Health, Inc: SWOT Analysis
Figure 10.30: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 10.31: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 10.32: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 10.33: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 10.34: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 10.35: Fitbit, Inc: Product Portfolio for Global Digital Biomarkers Market
Figure 10.36: Fitbit Inc.: Overall Financials, 2016-2018
Figure 10.37: Fitbit Inc.: Revenue (by Region), 2016-2018
Figure 10.38: Fitbit, Inc.: R&D Expenditure, 2016-2018
Figure 10.39: Fitbit Inc.: SWOT Analysis
Figure 10.40: GlaxoSmithKline Plc: Overall Financials, 2016-2018
Figure 10.41: GlaxoSmithKline Plc: Revenue (by Business Segments), 2016-2018
Figure 10.42: GlaxoSmithKline: Revenue (by Region), 2016-2018
Figure 10.43: GlaxoSmithKline Plc: R&D Expenditure, 2016-2018
Figure 10.44: GlaxoSmithKlin Plc SWOT Analysis
Figure 10.45: Human API: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.46: Human API: SWOT Analysis
Figure 10.47: Happify Health: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.48: Happify: SWOT Analysis
Figure 10.49: IXICO Plc: Product Portfolio for Global Digital Biomarkers Market
Figure 10.50: IXICO plc: Overall Financials, 2016-2018
Figure 10.51: IXICO plc: Revenue (by Region), 2016-2018
Figure 10.52: IXICO plc: R&D Expenditure, 2016-2018
Figure 10.53: IXICO plc: SWOT Analysis
Figure 10.54: Koninklijke Philips N.V.: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.55: Koninklijke Philips N.V.: Overall Financials ,2016-2018
Figure 10.56: Koninklijke Philips N.V.: Revenue (by Segment) ,2016-2018
Figure 10.57: Koninklijke Philips N.V.: Revenue (by Region), 2016-2018
Figure 10.58: Koninklijke Philips N.V.: R&D Expenditure, 2016-2018
Figure 10.59: Koninklije Philips N.V.: SWOT Analysis
Figure 10.60: Medopad Ltd: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.61: Medopad Ltd: SWOT Analysis
Figure 10.62: Mindstrong Health: Product Portfolio for the Global Digital Biomarkers Market
Figure 9.63: Mindstrong Health: SWOT Analysis
Figure 10.64: Neurotrack Technologies, Inc: Product Portfolio for Global Digital Biomarkers Market
Figure 10.65: Neurotrack Technologies, Inc: SWOT Analysis
Figure 10.66: Novartis International AG: Overall Financials, 2016-2018
Figure 10.67: Novartis AG: Revenue (by Segment), 2016-2018
Figure 10.68: Novartis AG: Revenue (by Region), 2016-2018
Figure 10.69: Novartis International AG, R&D Expenditure, 2016-2018
Figure 10.70: Novartis International AG: SWOT Analysis
Figure 10.71: Orikami: SWOT Analysis
Figure 10.72: Pfizer, Inc: Overall Financials, 2016-2018
Figure 10.73: Pfizer Inc: Revenue (by Segment), 2016-2018
Figure 10.74: Pfizer Inc: Revenue (by Region), 2016-2018
Figure 10.75: Pfizer Inc.: R&D Expenditure, 2016-2018
Figure 10.76: Pfizer Inc.: SWOT Analysis
Figure 10.77: Quanterix Corporation: Product Portfolio for Global Digital Biomarkers Market
Figure 10.78: Quanterix Corporation: Overall Financials, 2015-2017
Figure 10.79: Quanterix Corporation: Revenue (by Region), 2015-2017
Figure 10.80: Quanterix Corporation: R&D Expenditure, 2015-2017
Figure 10.81: Quanterix Corporation: SWOT Analysis
Figure 10.82: Sanofi S.A.: Overall Financials, 2016-2018
Figure 10.83: Sanofi: S.A. Revenue (by Business Segments), 2016-2018
Figure 10.84: Sanofi S.A.: Revenue (by Region), 2016-2018
Figure 10.85: Sanofi S.A.: R&D Expenditure 2016-2018
Figure 10.86: Sanofi S.A.: SWOT Analysis
Figure 10.87: The Takeda Pharmaceuticals Company Limited: Overall Financials, 2016-2018
Figure 10.88: The Takeda Pharmaceuticals Company Limited: Revenue (by Region), 2016-2018
Figure 10.89: The Takeda Pharmaceuticals Company Limited: R&D Expenditure, 2016-2018
Figure 10.90: The Takeda Pharmaceuticals Company Limited: SWOT Analysis
Figure 10.91: Verily Life Sciences: SWOT Analysis
Figure 10.92: Cambridge Cognition Plc: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.93: MC10 Inc: Product Portfolio for Global Digital Biomarkers Market
Note: Product cover images may vary from those shown

Loading
LOADING...

FEATURED COMPANIES

  • ActiGraph, LLC
  • Amgen Inc
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Koninklijke Philips N.V.
  • Mindstrong Health

With the recent technological advancements in the field of mobile and digitally connected technologies, the concept of biomarkers has diverged into a new class altogether called digital biomarkers. This new emerging concept of digital biomarkers has found implications in both clinical trials as well as clinical care. The technology enables the collection of consumers generated physiological and behavioral data with the help of digitally connected tools such as wearable, implantable, and ingestible devices and sensors.

Digital biomarkers conduct measurements over a wide range of categories such as diagnostic, prognostic, monitoring, and predictive. This tremendous growth rate of the digital biomarkers market is facilitated by several factors such as rapidly increasing uptake of smartphones, wearables, and the advent of high-speed networks and connectivity solutions.

Currently, there are approximately 2.0 billion smartphone users globally which are expected to reach nearly 6 billion in the coming years. Even the use of high-speed networks such as 3G and 4G is set to increase by 73% by the end of 2020. Also, from a health perspective, there is an ongoing demand for solutions that could efficiently minimize healthcare costs and help in the management of chronically ill patients.

According to the report, titled ‘Global Digital Biomarkers Market – Analysis and Forecast (2019-2025)’, the market is projected to grow at a CAGR of 40.39% during the forecast period from 2019 to 2025.

Key Questions Answered in the Report:


  • What are the total addressable market (TAM) and the potential market opportunity for the global digital biomarkers market?
  • What are the major market drivers and challenges of, and the opportunities in, the global digital biomarkers market?
  • What is the market share of the leading segments and sub-segments of the global digital biomarkers market in 2019 and 2025?
  • How did the global digital biomarkers market evolve?
  • How is each segment of the global digital biomarkers market expected to grow during the forecast period and what is the expected revenue to be generated by each of the segments by the end of 2025?
  • What are the consumer preferences in terms of the adoption of wearable technology for the assessment of medical conditions?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What is the preferred business model used for building digital biomarkers?
  • Which area of application is expected to be the highest revenue generator in the global digital biomarkers market during the forecast period?
  • Which end-user segment is expected to be the highest revenue generator in this industry during the forecast period?
  • What is the potential of the global digital biomarkers market in emerging countries during the forecast period?

 


Note: Product cover images may vary from those shown
  • ActiGraph, LLC
  • Akili Interactive Labs
  • AliveCor Inc.
  • Altoida Inc.
  • Amgen Inc
  • Bayer AG
  • Biogen Inc
  • Eli Lilly and Company
  • Evidation Health, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fitbit, Inc.
  • GlaxoSmithKline Plc
  • Human API
  • Happify Health
  • IXICO Plc
  • Koninklijke Philips N.V.
  • Medopad Ltd
  • Mindstrong Health
  • Neurotrack Technology, Inc
  • Novartis International AG
  • Orikami
  • Pfizer Inc.
  • Quanterix Corporation
  • Sanofi S.A.
  • The Takeda Pharmaceuticals Company Limited
  • Verily Life Sciences
  • Cambridge Cognition Plc
  • MC10 Inc.
  • Medical Care Corporation
  • Shimmer
  • Winterlight Labs Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...